1,710 Shares in Thermo Fisher Scientific Inc. (TMO) Acquired by Bredin Investment LLC
Bredin Investment LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,710 shares of the medical research company’s stock, valued at approximately $330,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of TMO. Bank of Nova Scotia Trust Co. purchased a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $106,000. Ropes Wealth Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 15.8% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after buying an additional 97 shares in the last quarter. Atlantic Trust LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $138,000. Acrospire Investment Management LLC raised its stake in shares of Thermo Fisher Scientific by 66.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock worth $174,000 after buying an additional 400 shares in the last quarter. Finally, Glassman Wealth Services raised its stake in shares of Thermo Fisher Scientific by 23.1% during the 2nd quarter. Glassman Wealth Services now owns 1,039 shares of the medical research company’s stock worth $181,000 after buying an additional 195 shares in the last quarter. 86.22% of the stock is owned by hedge funds and other institutional investors.
In other news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the sale, the chief executive officer now owns 252,577 shares in the company, valued at $47,582,981.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.49% of the stock is currently owned by corporate insiders.
Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. The firm had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. Thermo Fisher Scientific’s quarterly revenue was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.03 EPS. equities research analysts forecast that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Monday, January 15th. Shareholders of record on Friday, December 15th were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date was Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.
A number of equities analysts have recently issued reports on TMO shares. Barclays reissued an “overweight” rating and set a $215.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Goldman Sachs Group began coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price target on the stock. Jefferies Group restated a “hold” rating and issued a $195.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Leerink Swann upped their price target on Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a report on Monday, October 9th. Finally, Deutsche Bank set a $226.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, October 26th. Two equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus price target of $212.21.
COPYRIGHT VIOLATION WARNING: “1,710 Shares in Thermo Fisher Scientific Inc. (TMO) Acquired by Bredin Investment LLC” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/1710-shares-in-thermo-fisher-scientific-inc-tmo-acquired-by-bredin-investment-llc/1819416.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.